Skip to main content
Clinical Trials/NCT02584946
NCT02584946CompletedNot Applicable

Effect of Avenanthramides Supplement on Exercise-induced Physiological and Psychological Changes

PepsiCo Global R&D0 sites24 target enrollmentStarted: March 2, 2016Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
24
Primary Endpoint
Mean and SD of plasma concentrations of Creatine Kinase

Study Overview

Brief Summary

The aim of the proposed study is to examine whether long-term dietary supplementation (8 weeks) of an oat flour cookie rich in avenanthramides (AVA) could enhance blood antioxidant capacity and reduce blood inflammatory markers after a downhill running (DR) protocol among human subjects.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Basic Science
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
20 Years to 45 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •1. Male and female non-obese subjects (18kg/M2<BMI<28kg/M2) (age 20-45 years) will be recruited from the Twin Cities community. All participants will sign informed consent approved by UMN-IRB and are willing to avoid oat consumption and rigorous physical activity the day prior to and through test and to consume a low-polyphenol diet for 1 week prior to the study. The foods rich in polyphenols include all berries, apples, pears, citrus fruits, fruit juices, onions, chocolate, wine, coffee, tea, beans, nuts, soy products and most spices

Exclusion Criteria

  • •Presence of GI conditions that interfere with absorption;
  • •Clinically significant endocrine, cardiovascular, pulmonary, renal, hepatic, pancreatic, biliary or neurologic disorders;
  • •Major trauma or surgery within 3 months of visit;
  • •Cancer in the prior 2 years;
  • •Allergic to oat products;
  • •Women who are pregnant or lactating;
  • •Drinking alcohol >5 drinks/week;
  • •Using nutraceuticals;
  • •Blood pressure medication;
  • •NSAID (>800 mg ibuprofen/week)
  • •Vitamin supplementation
  • •Anticoagulants or hypoglycemic drugs
  • •Oat products consumption and rigorous physical activity the day before the test and consumption of a high-polyphenol diet in week prior to the test.
  • •Moderate-intensity cardiorespiratory exercise training for ≥30 min•d-1 on ≥5 d•wk-1 for a total of ≥150 min•wk-1, vigorous-intensity cardiorespiratory exercise training for ≥20 min•d-1 on ≥3 d•wk-1 (≥75 min•wk-1), or a combination of moderate- and vigorous-intensity exercise to achieve a total energy expenditure of ≥500-1000 MET•min•wk-1

Arms & Interventions

Low-AVA oat flour cookies

Placebo Comparator

Intervention: Avenanthramides (Other)

High-AVA oat flour cookies

Experimental

Intervention: Avenanthramides (Other)

Outcomes

Primary Outcomes

Mean and SD of plasma concentrations of Creatine Kinase

Time Frame: 0-72 hours

Secondary Outcomes

  • Mean and SD of plasma concentrations of TNF-α(0-72 hours)
  • Mean and SD of plasma concentrations of IL-6(0-72 hours)
  • Mean and SD of plasma concentrations of ICAM-1, VCAM-1, NF-κB (P65), NRB, NF-κB binding to DNA, 4-Hydroxynenenol, F2-isoprostane(0-72 hours)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials